Glenmark Takes Direct U.S. Control of RYALTRIS®

Glenmark Pharmaceuticals assumes end-to-end commercialization and distribution of RYALTRIS® in the U.S. effective April 1, 2026.
RYALTRIS® is Glenmark's first innovative product in the U.S., a fixed-dose nasal spray approved for Seasonal Allergic Rhinitis since 2022.
The product is now available in 55 countries globally, with 11 new market launches in FY26 alone.